Eisai's Fycompa approved in US with boxed warning, awaits DEA scheduling

Eisai's novel antiepileptic drug Fycompa (perampanel) has been approved by the US FDA after a bumpy regulatory ride, for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in epilepsy patients aged 12 or older.